To validate these results in primary human samples and to interrogate their relevance to tamoxifen-induced reduction of mutant allele burden in MPN, a longitudinal analysis of the transcriptome of CD34+ HSPCs was conducted on 16 study subjects before tamoxifen treatment and after 24-week tamoxifen treatment. Here, CD34 is linked to myeloproliferative disorder.